Page 17 - Read Online

Page 12 of 14 Monge Bonilla et al. Hepatoma Res 2020;6:68 I http://dx.doi.org/10.20517/2394-5079.2020.58

32. Sun C, Sun HY, Xiao WH, Zhang C, Tian ZG. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based
immunotherapy. Acta Pharmacol Sin 2015;36:1191-9.
33. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, et al. Myeloid derived suppressor cells inhibit natural killer cells in
patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009;50:799-807.
34. Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, et al. Blockade of immunosuppressive cytokines restores NK cell antiviral
function in chronic hepatitis B virus infection. PLoS Pathog 2010;6:e1001227.
35. Kong X, Sun R, Chen Y, Wei H, Tian Z. γδT cells drive myeloid-derived suppressor cell-mediated CD8+ T cell exhaustion in hepatitis B
virus-induced immunotolerance. J Immunol 2014;193:1645-53.
36. Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, et al; Hepatitis B Research Network. Hepatitis B virus--specific and global T-cell
dysfunction in chronic hepatitis B. Gastroenterology 2016;150:684-95.e5.
37. Wherry EJ. T cell exhaustion. Nat Immunol 2011;12:492-9.
38. Pallett LJ, Gill US, Quaglia A, Sinclair LV, Jover-Cobos M, et al. Metabolic regulation of hepatitis B immunopathology by myeloid-
derived suppressor cells. Nat Med 2015;21:591-600.
39. Pal S, Nandi M, Dey D, Chakraborty BC, Shil A, et al. Myeloid-derived suppressor cells induce regulatory T cells in chronically
HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy. Aliment Pharmacol Ther
2019;49:1346-59.
40. Kim GA, Lim YS, Han S, Choi J, Shim JH, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase
chronic hepatitis B. Gut 2018;67:945-52.
41. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during
persistent hepatitis B virus infection. J Exp Med 2000;191:1269-80.
42. Mason WS, Gill US, Litwin S, Zhou Y, Peri S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B
patients considered immune tolerant. Gastroenterology 2016;151:986-98.e4.
43. Fisicaro P, Barili V, Montanini B, Acerbi G, Ferracin M, et al. Targeting mitochondrial dysfunction can restore antiviral activity of
exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat Med 2017;23:327-36.
44. Amadei B, Urbani S, Cazaly A, Fisicaro P, Zerbini A, et al. Activation of natural killer cells during acute infection with hepatitis C virus.
Gastroenterology 2010;138:1536-45.
45. Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C virus and hepatocellular carcinoma: a narrative review. J Clin Transl Hepatol
2018;6:79-84.
46. Rosen HR, Golden-Mason L. Control of HCV infection by natural killer cells and macrophages. Cold Spring Harb Perspect Med
2019:a037101.
47. Gremion C, Grabscheid B, Wölk B, Moradpour D, Reichen J, et al. Cytotoxic T lymphocytes derived from patients with chronic hepatitis
C virus infection kill bystander cells via Fas-FasL interaction. J Virol 2004;78:2152-7.
48. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, et al. The outcome of hepatitis C virus infection is predicted by escape
mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001;15:883-95.
49. Ruhl M, Knuschke T, Schewior K, Glavinic L, Neumann-Haefelin C, et al; East German HCV Study Group. CD8+ T-cell response
promotes evolution of hepatitis C virus nonstructural proteins. Gastroenterology 2011;140:2064-73.
50. Radziewicz H, Ibegbu CC, Hon H, Osborn MK, Obideen K, et al. Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells
undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection. J
Virol 2008;82:9808-22.
51. Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, et al. High-programmed death-1 levels on hepatitis C virus-specific T cells
during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J
Immunol 2008;181:8215-25.
52. Owusu Sekyere S, Suneetha PV, Kraft AR, Zhang S, Dietz J, et al. A heterogeneous hierarchy of co-regulatory receptors regulates
exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. J Hepatol 2015;62:31-40.
53. McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kemper M, et al. Tim-3 expression on PD-1+ HCV-specific human CTLs
is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 2010;120:4546-57.
54. Chattergoon MA, Latanich R, Quinn J, Winter ME, Buckheit RW 3rd, et al. HIV and HCV activate the inflammasome in monocytes and
macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog 2014;10:e1004082.
55. Liu Y, Wang W, Zou Z, Hu Z, Fan Q, et al. Hepatitis C virus entry into macrophages/monocytes mainly depends on the phagocytosis of
macrophages. Dig Dis Sci 2019;64:1226-37.
56. He G, Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011;21:159-68.
57. Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol
2016;16:509-23.
58. Ren JP, Wang L, Zhao J, Wang L, Ning SB, et al. Decline of miR-124 in myeloid cells promotes regulatory T-cell development in
hepatitis C virus infection. Immunology 2017;150:213-20.
59. Farooqi ZU, Tareen SH, Ahmed J, Zaidi NU. Logical analysis of regulation of interleukin-12 expression pathway regulation during HCV
infection. Protein Pept Lett 2016;23:581-9.
60. Piconese S, Timperi E, Pacella I, Schinzari V, Tripodo C, et al. Human OX40 tunes the function of regulatory T cells in tumor and
nontumor areas of hepatitis C virus-infected liver tissue. Hepatology 2014;60:1494-507.
61. Della Bella S, Crosignani A, Riva A, Presicce P, Benetti A, et al. Decrease and dysfunction of dendritic cells correlate with impaired